Center for Systems Biomedicine, University of California at Los Angeles , Los Angeles, California.
Center for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles , Los Angeles, California.
Am J Physiol Gastrointest Liver Physiol. 2018 Feb 1;314(2):G256-G262. doi: 10.1152/ajpgi.00268.2017. Epub 2017 Nov 16.
Inflammatory bowel diseases (IBD) are chronic inflammatory gastrointestinal diseases, primarily consisting of ulcerative colitis and Crohn's disease. The complex nature of the disease, as well as the limited therapeutic options characterized by low efficiency and major side effects, highlights the importance of developing novel strategies of therapeutic intervention in IBD. Susceptibility loci related to IBD are present only in a small percentage of IBD patients, implying that epigenetic modifications could influence the pathogenesis of the disease. MicroRNAs (miRNAs) are small noncoding RNAs that regulate multiple molecular pathways involved in IBD pathobiology. MiRNA inhibitors targeting the IBD-activated miRNAs could have therapeutic value for IBD patients. This review provides an overview of the recent advances in miRNA biology related to IBD pathogenesis and the pharmacological development of miRNA-based therapeutics.
炎症性肠病（IBD）是一种慢性炎症性胃肠道疾病，主要包括溃疡性结肠炎和克罗恩病。该疾病的复杂性，以及治疗方法有限，效率低且副作用大，这凸显了开发新型治疗干预策略在 IBD 中的重要性。与 IBD 相关的易感性基因座仅存在于一小部分 IBD 患者中，这意味着表观遗传修饰可能会影响疾病的发病机制。微小 RNA（miRNA）是一种调节与 IBD 病理生物学相关的多种分子途径的小非编码 RNA。针对 IBD 激活 miRNA 的 miRNA 抑制剂可能对 IBD 患者具有治疗价值。本综述概述了与 IBD 发病机制相关的 miRNA 生物学的最新进展，以及 miRNA 为基础的治疗方法的药理学进展。
